维普中文期刊产品整合服务
75篇 您的检索式:作者名="Evora"
    题名 作者 年代 出处 被引量
1中国澳门非瓣膜病性心房颤动患者的栓塞及抗凝治疗临床调查显示文摘目的:通过对仁伯爵综合医院就诊的非瓣膜病性心房颤动(房颤)患者数据的分析,揭示中国澳门非瓣膜病性房颤患者抗栓治疗的现状。方法:纳入2014-01至2014-12期间共472例非瓣膜病性房颤患者,平均年龄为(73.4±10.9)岁,女性197例(41.7%),年龄≥75岁的患者244例(51.7%)。分析患者的一般特征、临床特征及抗栓治疗,并计算CHA2DS2-VASc评分,评分≥2分为卒中高危;计算HAS-BLED评分,评分≥3分为出血高危。结果:472例患者的平均CHA2DS2-VASc评分为(3.4±1.8)分,CHA2DS2-VASc≥2分的患者有389例(82.4%);平均HAS-BLED评分为(1.96±1.03)分,HAS-BLED评分≥3分的患者有132例(28.0%)。接受抗血小板治疗的患者184例(38.9%),华法林101例(21.6%),新型口服抗凝药物156例(33.8%);同时接受抗血小板和抗凝治疗的患者22例(4.6%);未用任何抗栓治疗的患者53例(11.2%)。卒中高风险患者抗凝治疗率高,215例(55.3%)CHA2DS2-VASc评分≥2分的患者接受了抗凝治疗,新型抗凝药物应用比例超过华法林。结论:中国澳门地区非瓣膜病性房颤患者具有较高的卒中风险,超过80%的患者CHA2DS2-VASc评分≥2分,多数患者依据卒中危险评分进行抗凝治疗,55.3%的患者接受了抗凝治疗,且新型口服抗凝药物应用超过华法林。陈若菡 穆岱明 林如波 叶文辉 Jose Lima 招漫玲 Kyisoe Mario Evora 陈柯萍 2016中国循环杂志2016,31,12:6
2Trans-brachial artery access for coronary artery procedures is feasible and safe: data from a single-center in Macao显示文摘Compared with trans-femoral artery access (TFA), trans-radial artery access (TRA) for percutaneous coronary interventions (PCI) has been shown to significantly reduce 30-day mortality, in-hospital major adverse cardiac and cardiovascular events (a composite of 30-day mortality and in-hospital myocardial re-infarction, target vessel revascularization, and cerebrovascular events), major bleeding, and access site complications.[1] TRA is more easily compressible, minimizing hematoma risk, and lower crossover rates to another access. Patients may ambulate immediately after procedure, that hospitalization can be shortened significantly. In some centers, patient with TRA can be discharged on the same day of procedure. It is also superior to TFA with closure devices, and becomes the preferred access site for recent PCI.[2]U Po Lam Edmundo Patricio Lopes Lao Kan Chit Lam Mario Evora Na-Qiong Wu 2019Chinese Medical Journal2019,,12:2
3Murine Recombinant Angiotensin-Converting Enzyme 2: Effect on Angiotensin II–Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2显示文摘Minghao Ye Jan Wysocki Francisco R. Gonzalez-Pacheco Mahmoud Salem Karla Evora Laura Garcia-Halpin Marko Poglitsch Manfred Schuster Daniel Batlle 2012Hypertension2012,,3:2
4The aging burden of hospitalization for heart failure in Chinese populations:evidence from the Macao Heart Failure Study显示文摘Objective To assess the aging burden of hospitalization for heart failure in Chinese populations in Macao.Methods The Macao Heart Failure Study consists of patients hospitalized with a diagnosis of acute heart failure(AHF)at Centro Hospitalar Conde de São Januário(the only public hospital that provides medical care for the approximately 600,000 residents of Macao)from January 2014 to December 2016.First,we investigated the relationship between socioeconomic development and epidemiological characteristics of HF in Macao.Then we assessed the patients’clinical features and outcomes according to the age groups.Results A total of 967 patients were included in the final analysis.The median age at admission was 82 years old.The advanced age at the admission of HF in Macao was significantly associated with a high-income level and the aging population structure.Marked heterogeneity existed in the epidemiological characteristics,clinical features,utilization of evidence-based therapies,short-and long-term outcomes,and prognostic utility of clinical variables among the different age groups.Conclusion Rapid economic development and significantly aging populations have produced a profound impact on the epidemiological characteristics of HF in Chinese populations.Acute decompensated heart failure(ADHF)is predominantly a disease of the elderly in Macao,and a significant heterogeneity exists in the clinical features,managements,and outcomes among different age groups.Age-based risk stratification models and multidisciplinary HF teams are urgently needed to improve the management and outcomes of hospitalized heart failure(HHF)patients.Zhi-Nan LU Mario Evora Edmundo Lao Man Ieng Pun Weng Hong Pun Monica Pon Kong Chu Pui I Ieong Toi-Meng Mok Yong-Jian WU 2020Journal of Geriatric Cardiology2020,17,9:2
5Efficacy and safety of apretinin use for reoperative valvular surgery 显示文摘Rodrigues AJ Evora PR Bassetto S a al 2007Ann Thorac Surg2007,83,6:1
6Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylc holine显示文摘Evora C Soriano I Rogers RA 1998J Controlled Release1998,51,23:1
7Fabrication,Characterization and Dynamic Behavior of Polyester/TiO2 Nanocomposites显示文摘Evora Victor M F Shukla Arun 2003Materials Science and Engineering A2003,25,12:1
8Impaired endothelium-dependent relaxation after coronary reperfusion injury:Evidence for G-protein dysfunction显示文摘Evora PR Pearson PJ Schaff HV 1994Ann Thorac Surg1994,57,6:1
9Blood cardioplegia with N-acetylcysteine may reduce coronary endothelial activation and myocardial oxidative stress显示文摘Rodrigues AJ Evora PR Bassetto S 2009Heart Surg Forum2009,12,1:1
10Effects of an inspiratory mus- cle rehabilitation program in the postoperative period of cardiac surgery显示文摘Ferreira PE Rodrigues A J Evora PR 2009Arq Bras Cardiol2009,92,4:1
11PLA-PEG particles as nasal protein carriers: the influence of the particle size 显示文摘Vila A Sanchez A Evora C 2005Int J Pharm2005,292,12:1
12A variant technique for thesurgical treatment of left ventricular aneurysms显示文摘Evora PR Tubino PV’Gali LG 2014Rev Bras CirCardiovasc2014,29,4:1
13The adsorption of poly(vinyl alcohol) to biodegradable microparticles studied by X-Ray photoelectron spectroscopy(XPS)显示文摘Shakesheff K M Evora C Soriano I 1997J Coll Interface Sci1997,185,2:1
14PLA-PEG particles as nasal protein carriers:the influence of the particle size显示文摘Vila A S6nchez A Evora C 2005Int JPharm2005,292,12:1
15Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: Influence of gamma sterilization显示文摘Soriano A Y Martin C Evora 2006BiomedMaterResA2006,77,3:1
16Efficacy andsafety of apretinin use for reoperative valvular surgery显示文摘Rodrigues AJ Evora PR Bassetto S 2007AnnTh orac Surg2007,83,:1
17One-month sustained release microspheres of I-bovine calcitonin in vitro--in vivo studies 显示文摘RV Diaz M Llabres C Evora 1999Controlled Release1999,59,:1
18Fabrication, characterization, and dynamic behavior of polyester/TiOz nanocomposites 显示文摘Victor M EVora F Arun S 2003Materials Science and Engineering2003,361,:1
19Formulation of Calcium Phosphates/Poly (d, 1-lactide) blends containing gentmnicin for bone implantation 显示文摘Soriano I Evora C 2000J Control Release2000,68,:1
20Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry : the effect of 1,2-dipalmitoylphosphatidylcholine 显示文摘EVORA C SORIANO I ROGERS RA 1998J Control Release1998,51,23:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费